Western University

Scholarship@Western
Brain and Mind Institute Researchers'
Publications

Brain and Mind Institute

10-1-2014

Dopaminergic therapy affects learning and impulsivity in
Parkinson's disease.
Nole M Hiebert
Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada, N6A 5B7 & Department
of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada, N6A 5C1

Ken N Seergobin
Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada, N6A 5B7

Andrew Vo
Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada, N6A 5B7 & Department
of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada, N6A 5C1

Hooman Ganjavi
Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada,
N6A 5C1

Penny A MacDonald
Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada, N6A 5B7 & Department
of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada, N6A 5C1 &
Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada,
N6A 5C1 & Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario,
Canada, N6A 5C1
Follow this and additional works at: https://ir.lib.uwo.ca/brainpub
Part of the Neurosciences Commons, and the Psychology Commons

Citation of this paper:
Hiebert, Nole M; Seergobin, Ken N; Vo, Andrew; Ganjavi, Hooman; and MacDonald, Penny A,
"Dopaminergic therapy affects learning and impulsivity in Parkinson's disease." (2014). Brain and Mind
Institute Researchers' Publications. 264.
https://ir.lib.uwo.ca/brainpub/264

RESEARCH ARTICLE

Dopaminergic therapy affects learning and impulsivity in
Parkinson’s disease
Nole M. Hiebert1,2, Ken N. Seergobin1, Andrew Vo1,3, Hooman Ganjavi4 &
Penny A. MacDonald1,2,3,5
1

Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada, N6A 5B7
Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada, N6A 5C1
3
Department of Psychology, University of Western Ontario, London, Ontario, Canada, N6A 5C2
4
Department of Psychiatry, University of Western Ontario, London, Ontario, Canada, N6A 5W9
5
Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada, N6A 5A5
2

Correspondence
Penny A. MacDonald, Brain and Mind
Institute, Natural Sciences Centre, Room 226,
University of Western Ontario, London,
Ontario, Canada, N6A 5B7. Tel: 1 519 6858500 ext. 33631; Fax: 519 663-3753; E-mail:
penny.macdonald@gmail.com
Funding Information
This work was supported by start-up funds
and an Opportunity Grant from the
Academic Medical Organization of
Southwestern Ontario awarded to Penny A.
MacDonald.
Received: 3 May 2014; Revised: 29 July
2014; Accepted: 4 September 2014
Annals of Clinical and Translational
Neurology 2014; 1(10): 833–843
doi: 10.1002/acn3.128

Abstract
Objective: The aim was to examine the effect of dopaminergic medication on
stimulus-response learning versus performing decisions based on learning.
Method: To see the effect of dopaminergic therapy on stimulus-response learning and response selection, participants with Parkinson’s disease (PD) were
either tested on and/or off their prescribed dose of dopaminergic therapy during different testing days. Forty participants with PD and 34 healthy controls
completed the experiment on consecutive days. On Day 1, participants learned
to associate abstract images with spoken, “right” or “left” responses via feedback (Session 1). On Day 2, participants recalled these responses (Session 2)
and indicated the location (i.e., right or left of center) of previously studied
images intermixed with new images (Session 3). Results: Participants with PD
off medication learned stimulus-response associations equally well compared to
healthy controls. Learning was impaired by dopaminergic medication. Regardless of medication status, patients recalled the stimulus-response associations
from Day 1 as well as controls. In Session 3 off medication, patients demonstrated enhanced facilitation relative to controls and patients on medication,
when the stimulus location was congruent with the spoken response that was
learned for the stimulus in Session 1. Interpretation: Learning in PD was comparable to that of healthy controls off medication. Learning was worsened by
dopaminergic therapy in PD. We interpret greater facilitation in participants
with PD off medication for congruent responses as evidence of greater impulsivity. This motor or reflexive impulsivity was normalized by medication in
PD. These findings shed light on the cognitive profile of PD and have implications for dopaminergic treatment.

Introduction
Parkinson’s disease (PD) is a neurodegenerative illness
with prominent motor symptoms of tremor, bradykinesia,
and rigidity. These motor symptoms result from degeneration of the dopamine-producing cells of the substantia
nigra (SN), leading to dopamine deficiency and dysfunction in the dorsal striatum (DS). Cognitive dysfunction
has long been recognized as a feature of PD.1 The causes
of cognitive impairments in PD are complex and the
effect of dopaminergic therapy on cognition is variable.

The cognitive profile in PD has many determinants.
Increasingly, it is evident that the striatum itself mediates
cognitive functions.2 In PD, some cognitive deficits relate
to dopamine depletion in DS and are remediated, at least
partially, by dopaminergic therapy. Other cognitive deficits arise as a consequence of dopaminergic therapy.2–5
Increasingly, it is understood that this occurs due to overdose of brain regions that receive dopamine from the
ventral tegmental area (VTA) that is relatively spared in
PD.2–5 These regions include ventral striatum (VS), prefrontal, and limbic cortices.2 Finally, some abnormalities
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likely relate to changes in other neurotransmitter systems,
cortical degeneration, and Lewy body deposition, and are
therefore neither improved nor worsened by dopaminergic therapy.6–8
The current study explored cognition in PD and the
effect of dopaminergic medication. We investigated learning and later recalling stimulus-response associations as
well as the influence of previously learned associations on
response selections. The aim of the study was to understand the effect of dopaminergic medication on learning
stimulus-response associations and performing decisions
based on that learning.
Dopaminergic therapy has been shown to negatively
impact various forms of learning.5,9–13 However, studies
that examine learning often neglect to separately assess
the acquisition of associations between stimuli, responses,
and outcomes from response selection processes that rely
on the learned associations. For instance, a characteristic
stimulus-response learning paradigm proceeds as follows:
(1) a stimulus is presented and participants decide
amongst the possible responses, (2) feedback pertaining to
the accuracy of the response is given, through which the
association is learned. An estimation of stimulus-response
association learning is obtained by measuring the accuracy
of stimulus-specific responses.14,15 Impairment in either
learning the associations or using the learned information
to decide among a set of responses could yield poor performance in these typical learning scenarios.
Atallah and colleagues16 elegantly address this point.
An overwhelming literature exists that implicates DS in
mediating learning associations among stimuli, responses
and rewards.17,18 However, noting the above confound
between learning associations and performance, Atallah
and colleagues separated association learning from performing responses based on that learning. In a Y-maze
task using odor cues, rats receiving infusions of inhibitory
gamma-amino butyric acid (GABA) to DS were unable to
consistently choose a rewarded versus unrewarded arm
compared to saline-infused rats during the learning period of the experiment. On the surface, this seemed to
suggest that inhibitory GABA infusions to DS impaired
the rat’s ability to learn the associations between odor
cues and rewards. However, the infusions were later
stopped and both the experimental and control groups
performed the task similarly. This demonstrated that during the learning period, associations were learned equally
well for both the experimental and control groups and
inhibition of DS by GABA infusions impaired the rat’s
ability to use the learned associations to perform consistently rewarded selections. To supplement this finding, a
separate experiment performed by the same group found
that inhibiting DS by GABA infusions during the test
phase impaired selection performance compared to the
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control (i.e., saline-infused) rats, even though both groups
had previously shown identical learning of the odor cuereward associations during the learning period. Together,
these results challenge the notion that DS mediates learning and alternatively suggest a role in performing learned
responses.
The literature implicating learning impairment in PD
by dopaminergic medication similarly requires reconsideration. Several studies have failed to see impairment in
learning due to dopaminergic therapy.19,20 The aim of the
present study was to investigate the effect of dopaminergic therapy in PD on learning stimulus-response associations versus enacting the learned responses. In an
additional session, we investigated the effect of these variables on how response bias facilitates or interferes with
performance.

Materials and Methods
Participants
Forty participants with PD and 34 age- and educationmatched healthy controls participated in this experiment.
All participants with PD were previously diagnosed by a
licensed neurologist, had no coexisting diagnosis of
dementia or another neurological or psychiatric disease,
and met the core assessment for surgical interventional
therapy and the UK Brain Bank criteria for the diagnosis
of idiopathic PD.21 All PD and no control participants
were treated with dopaminergic therapy. Age- and education-matched controls consisted of friends, spouses, or
relatives of participants with PD who were similar in age
and education. For the minority of participants with PD
who could not recruit a healthy control of their own,
participants were recruited from a pool of healthy controls in Sudbury, Ontario, or through advertisements on
the University of Western Ontario campus. Healthy controls were required to be within 5 years of age and
5 years of education to the matched PD patient. Participants with PD were recruited through a patient database
created in Sudbury, Ontario or the movement disorders
database at the London Health Sciences Center. Participants abusing alcohol, prescription or street drugs, or
taking cognitive-enhancing medications including donepezil, galantamine, rivastigmine, or memantine were
excluded from participating. No participants with PD
were diagnosed with an impulse control disorder. Four
PD and four control participants performed less than
50% of the associations correctly either in Session 1 or 2,
explained below, and a further patient with PD scored
less than 20 on the montreal cognitive assessment
(MOCA), and therefore his/her data were not included in
the analysis.
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The motor sub-scale of the Unified Parkinson’s Disease
Rating Scale (UPDRS) was scored by a licensed neurologist with sub-specialty training in movement disorders (P.
A. M.) to assess the presence and severity of motor symptoms for all patients both on and off dopaminergic medication. Control participants were also screened to rule
out undiagnosed neurological illness. Mean group demographics, as well as cognitive and affective screening
scores for all patients and controls in each experimental
group were recorded (Table 1). UPDRS motor subscale
scores on and off dopaminergic therapy, daily doses of
dopamine replacement therapy in terms of ι-3,4-dihydroxyphenylalanine (L-dopa) equivalents, and mean duration of PD were also recorded (Table 1). Calculation of
daily ι-dopa equivalent dose for each patient was based
on the theoretical equivalence to ι-dopa as follows:
ι-dopa dose 9 1 + ι-dopa controlled release 9 0.75 +
ι-dopa 9 0.33 if on entacapone + amantadine (mg) 9
0.5 + bromocriptine (mg) 9 10 + cabergoline (mg) 9
50 + pergolide (mg) 9 100 + pramipexole (mg) 9 67 +
rasagiline (mg) 9 100 + ropinirole (mg) 9 16.67 + selegiline (mg) 9 10.22
There were no significant demographic differences
between PD and control participants (Table 1). Participants with PD scored significantly higher on both Beck
Depression Inventory II and Beck Anxiety Inventory compared to controls. Participants with MOCA scores less
than 20 were excluded from analysis. No differences were
found in terms of depressive or anxiolytic symptoms
between participants with PD measured on or off their
dopaminergic medication. UPDRS scores were significantly higher in participants with PD measured off relative to on dopaminergic medication, which is expected.
All participants provided informed written consent to
the protocol before beginning the experiment, according
to the Declaration of Helsinki (2013). All participants
with PD were competent and had the capacity to provide
informed consent. This study was approved by the Health
Sciences Research Ethics Board of the University of Western Ontario and the Ethics Review Board of the Sudbury
Regional Hospital.

Experimental design
Participants with PD were randomly divided into four subgroups and all participated in three experimental sessions
conducted over two consecutive days, as did their matched
healthy controls (Fig. 1). Participants with PD in Group 1
(OFF-ON) performed Session 1, on Day 1, off and Sessions 2 and 3, on Day 2, on dopaminergic medication,
whereas patients in Group 2 (ON-OFF) performed Session
1, on Day 1, on medication and Sessions 2 and 3, on Day
2, off medication. Group 3 (OFF-OFF) performed all
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sessions off dopaminergic therapy, whereas Group 4 (ONON) performed all sessions on dopaminergic medication.
Despite the four-group design, it was our intention to collapse into ON and OFF groups for Sessions 1 and 2,
respectively, to increase power. We found no differences
between ON and OFF groups in either Session in terms of
age or disease duration. We expected that dopaminergic
medication might have an effect on learning in Session 1.
Performance in Session 2 depended on how well stimulusresponse associations were learned in Session 1. To diminish any carry-over effects from Session 1, we (1) excluded
participants who performed less than 50% of the associations correctly in Session 1 or 2 and (2) included a similar
number of participants who learned ON as OFF in Session
1, in both the ON and OFF conditions in Session 2.
Although control participants did not take dopaminergic medication during any session, their data were analyzed to correspond to the medication order of the
participants with PD to whom they were matched.
Matching was performed prior to data analysis at the
time of experimentation. This controlled for possible
order, fatigue, and practice effects. Participants with PD
took their dopaminergic medication as prescribed by their
treating neurologist during ON testing sessions, but
abstained from taking all dopaminergic medications
including: dopamine precursors such as ι-dopa, aromaticL-amino-acid decarboxylase inhibitors such as carbidopa,
and catechol-O-methyltransferase (COMT) inhibitors
such as entacapone (Comtan) for a minimum of 12 to a
maximum of 18 h, and dopamine agonists, such as pramipexole (Mirapex), ropinirole (Requip) or pergolide (Permax), as well as amantadine (Symmetrel), rasagiline
(Azilect), and selegiline (Eldepryl or Deprenyl) for 16–
20 h before beginning OFF testing sessions. All patients
confirmed that they complied with these instructions.
All sessions of the experiment were performed using a
14.0″ widescreen laptop (Lenovo T420; Lenovo, Morrisville, North Carolina, USA) running a resolution of
1600 9 900 on the Windows 7 operating system. The
screen was placed at a distance of ~50 cm in front of the
participant and angled for optimal viewing.
Participants performed a task where they learned to
associate six abstract images with one of two spoken
responses, either “right” or “left”, via feedback (Session
1). Images consisted of characters taken from the
invented Klingon alphabet (Fig. 2). During each trial in
Session 1, an image appeared in the center of the computer screen until the participant responded with a verbal
response. Images would appear one at a time and in random order. Feedback, either the word “correct” or
“incorrect,” was presented after every response. In this
way, participants learned to associate each image with the
appropriate verbal response through trial and error.
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64.26
65.29
63.22
64.66
65.31
64.00

64.06
62.13
66.00
64.58
62.79
66.38

35
16
19
30
14
16

Age

35
17
18
30
16
14

n

(1.23)
(1.82)
(1.67)
(1.33)
(1.94)
(1.82)

(1.26)
(1.81)
(1.76)
(1.37)
(1.86)
(1.99)
14.71
14.69
14.74
14.09
14.00
14.19

14.73
15.35
14.11
14.06
14.63
13.50

Edu

(0.48)
(0.71)
(0.65)
(0.52)
(0.76)
(0.71)

(0.47)
(0.67)
(0.66)
(0.51)
(0.66)
(0.74)
6.37 (0.86)
6.00 (1.26)
6.77 (1.16)
–
–
–

6.36 (0.83)
5.12 (1.19)
7.61 (1.15)
–
–
–

Duration

572.06 (57.05)
555.80 (84.06)
588.32 (77.14)
–
–
–

574.01 (58.36)
593.46 (81.51)
554.56 (79.21)
–
–
–

ι-dopa (mg)

17
9
8
–
–
–

17
7
10
–
–
–

DA (n)

–
–
16.25 (1.67)
–
–
–
–
–
18.16 (1.67)
–
–
–

–
13.19 (0.80)
–
–
–
–

UPDRS OFF

–
13.91 (1.25)
–
–
–
–

UPDRS ON

124.81
125.54
124.08
123.11
122.52
123.70

124.71
123.37
126.04
123.16
123.01
123.31

ANART

(1.05)
(1.55)
(1.42)
(1.13)
(1.66)
(1.55)

(1.04)
(1.49)
(1.45)
(1.13)
(1.54)
(1.64)
9.83
10.88
8.79
3.21
3.86
2.56

10.67
10.12
11.22
4.11
3.94
4.29

BDI-II

(0.88)
(1.30)
(1.19)
(0.95)
(1.39)
(1.30)

(0.95)
(1.36)
(1.32)
(1.03)
(1.40)
(1.50)

9.46
9.81
9.11
2.15
2.86
1.44

12.24
12.77
11.72
4.00
5.50
2.50

BAI

(1.08)
(1.59)
(1.46)
(1.16)
(1.70)
(1.59)

(1.39)
(1.99)
(1.94)
(1.50)
(2.05)
(2.19)

11.96
11.19
12.74
9.55
10.36
8.75

12.07
10.59
13.56
10.37
10.81
9.93

(0.81)
(1.20)
(1.10)
(0.88)
(1.28)
(1.20)

(0.88)
(1.27)
(1.23)
(0.96)
(1.31)
(1.40)

Apathy

25.83
25.56
26.11
27.08
27.29
26.88

25.85
25.59
26.11
27.05
27.25
26.86

(0.42)
(0.61)
(0.56)
(0.45)
(0.66)
(0.61)

(0.42)
(0.60)
(0.58)
(0.45)
(0.61)
(0.66)

MOCA

Values are presented as group means (SEM). Screening cognitive and affective measures were completed by participants with PD on medication unless they performed both days off dopaminergic medication. Control participants did not receive dopaminergic therapy during any session of the experiment. Their data are presented to correspond to the ON-OFF order of the patient with
Parkinson’s disease to whom they were matched. All control participants presented with normal neurological exams. Day 1 refers to the first day of testing when Session 1 was completed. Day 2
refers to the second day of testing when Sessions 2 and 3 were completed. Edu, years of education; Duration, years since diagnosis of PD; ι-dopa, daily ι-dopa equivalent dose in mg; DA, number of participants with PD taking DA agonists; UPDRS ON, Unified Parkinson’s Disease Rating Scale motor score on medication; UPDRS OFF, Unified Parkinson’s Disease Rating Scale motor score
off medication; ANART, National Adult Reading Test IQ Estimation; BDI-II, Beck Depression Inventory II score measured for participants with PD and for matched control participants; BAI, Beck
Anxiety Inventory I score measured for participants with PD and for matched control participants; Apathy, Apathy Evaluation Scale score measured for participants with PD and for matched control participants; MOCA, Montreal Cognitive Assessment measured for participants with PD and for matched control participants.

Day 1
PD
ON
OFF
Control
ON
OFF
Day 2
PD
ON
OFF
Control
ON
OFF

Group

Table 1. Demographic, clinical information, and screening cognitive and affective measures for participants with PD and controls.
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Figure 1. Experimental design. Half of participants completed the
learning phase (Session 1) off medication; the other half learned on
medication in Session 1. An equal number in each the OFF and ON
groups in Sessions 2 and 3 learned the associations off or on
medication in Session 1.

Striatum in Learning and Impulsivity

Session 2 involved recall of the verbal response learned
for each of the six images on the previous day. Each
image appeared one at a time in random order for a total
of 72 trials, or 12 trials per image. No feedback was provided in Session 2 to preclude new, feedback-based learning of the associations.
In Session 3, completed immediately following Session 2,
on Day 2 of the experiment, the six images learned in Session 1 were presented with six new Klingon characters one
at a time, in random order. These images were presented
either on the left or the right side of the screen and the participant responded verbally with the side of the screen on
which the image appeared as quickly and accurately as they
could. Session 3 consisted of 144 trials. No feedback was
provided in this session. Examples of the order of events
for trials in each session are presented in Figure 3.

Data analysis
Efficiency of learning stimulus-response associations was
measured by calculating the slope of learning in Session
1. Session 1 was divided into 12 discrete blocks of 18
trials. At the end of a block, a score summarizing the
number of correct trials was logged but not revealed to
the participant. Slope was calculated using the standard
slope of the linear regression function in Microsoft Excel
(2011), given by the following equation:
P
ðx  xÞðy  yÞ
b¼
P
ðx  xÞ2

Figure 2. Abstract images presented in the experiment. (A) Learned
images refer to the images that were studied and associated with a
specific “right” or “left” response via deterministic feedback in
Session 1. These learned images were later presented at test in
Session 2. In Session 3 these learned images created the conditions
for the congruent and incongruent conditions. (B) Control images
refer to the images presented only in Session 3 that constituted the
control condition.

Session 1 consisted of 216 image and verbal response trials and at the end of the session participants were given a
percentage score, summarizing the number of correct
responses provided. Session 1 was completed on the first
day of testing, whereas Sessions 2 and 3 were completed
on the following day.

where b is the slope, and x and y are the sample means of
the number of blocks, and block scores, respectively.
Larger slope values signified faster learning of the stimulus-response associations. Session 2 was divided into four
discrete blocks of 18 trials and scores summarizing the
number of correct trials were logged, as in Session 1. Performance in Session 2 was measured by the average proportion of erroneous responses to the images based on
the associations learned in Session 1.
Three conditions – congruent, incongruent, and control
– were created in Session 3. In the congruent condition,
an image appeared in a location that was consistent with
the spoken response that had been learned for that image
during Session 1. In the incongruent condition, an image
appeared in a location that was opposite to the spoken
response that had been learned for that image during Session 1. In the control condition a new image that was not
previously associated with “right” or “left” was presented.
Session 3 consisted of 48 congruent, 48 incongruent, and
48 control trials that occurred in random order. Response
times were measured from the onset of the image until
the microphone recorded the participant’s response. The
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control condition provided a baseline for providing a
location response. Facilitation was calculated as mean
response times in the congruent condition minus those in
the control condition and interference was calculated as
mean response times in the incongruent condition minus
those in the control condition. Trials with a response
time greater than 2.5 standard deviations from the mean
were excluded from analysis.

Results
Session 1: Learning phase

Figure 3. Example of a single trial in Sessions 1, 2, and 3. (A)
Participants with PD and age- and education-matched controls learned
to associate six abstract images with either a “left” or “right” verbal
response in Session 1. The following is an example of a trial: (1) a
fixation cross appeared in the center of the computer screen for
700 msec; (2) a blank screen was presented for 300 msec; (3) an
image was presented in the center of the computer screen until the
participant vocalized a response that was recorded by the microphone;
(4) the image disappeared and the experimenter coded the response
using a keyboard; (5) feedback, either the word “correct” or
“incorrect” was presented for 750 msec before the next trial began.
(B) Participants recalled the responses to the learned images in the
absence of feedback in Session 2. (C) Images appeared on the left or
right side of the screen and participants indicated the location of the
images (either left or right of center) with a vocal response. Stimuli
included the six learned images presented in Sessions 1 and 2 as well
as six new images. Trials in Sessions 2 and 3 were identical to Session 1
except that feedback was omitted in both and the images appeared on
the left and right side of the screen in Session 3.

838

The average slope of learning to associate six images from
the Klingon alphabet with one of two spoken responses,
either “right” or “left”, via feedback was calculated for
participants with PD and controls in each of the ON and
OFF sessions (Fig. 4A). We performed a 2 9 2 analysis of
variance (ANOVA) on the slope. To reiterate, slope was
calculated using the percentage scores for the number of
correct responses obtained after each of the 12 blocks in
Session 1. Group (PD vs. Control) and Medication Session (OFF vs. ON) were between-subject factors. The
Group 9 Medication Session interaction was significant,
F1,61 = 3.99, MSE = 0.00, P = 0.050, though the main
effect of Group, F1,61 = 1.49, MSE = 0.00, P = 0.226, and
of Medication Session, F1,61 < 1, were not.
To further explore the significant Group 9 Medication
Session interaction, separate one-way ANOVAs were performed for PD and control participants, with Medication
Session (ON vs. OFF) as the between-subject factor. The
main effect of Medication Session was significant for participants with PD, F1,33 = 4.62, MSE = 0.000, P < 0.050,
reflecting slower learning on relative to off dopaminergic
medication, but not for control participants, F1,28 < 1.
We next compared learning slopes for PD patients ON
versus OFF medication relative to those of healthy controls. Because control participants’ performance did not
differ across the ON versus OFF Medication Sessions, we
collapsed into a single control group. As a reminder, control participants did not take dopaminergic medication
during any session of this experiment and their pseudoON versus pseudo-OFF status was assigned before participation to correspond to the group and order of the PD
patient to whom they were matched. Two one-way
ANOVAs were performed with Group (PD ON vs. Control; PD OFF vs. Control) as the between-subject factor.
There was a trend toward a significant difference in terms
of learning slopes for PD ON compared to the collapsed
control group, F1,45 = 3.90, MSE = 0.00, P = 0.055,
reflecting slower learning for PD patients on dopaminergic medication. There was no significant difference
between PD OFF and controls, F < 1.
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Figure 4. Effect of dopaminergic therapy on association learning,
facilitation and interference. (A) Slopes of learning in Session 1 for
participants with Parkinson’s disease (PD) and healthy control
participants. Average slopes of each medication group are presented.
Error bars represent standard error of the mean. Slopes were
calculated using the standard slope of the linear regression function
in Microsoft Excel (2011). The slope of learning for participants with
PD off dopaminergic medication is significantly higher than
participants with PD on medication (F1,33 = 4.62, MSE = 0.000,
P < 0.050). There was a trend toward a significant difference in terms
of learning slopes for PD on medication compared to the collapsed
control group, F1,45 = 3.90, MSE = 0.00, P = 0.055, reflecting slower
learning for PD patients on dopaminergic medication. (B) Mean
facilitation scores for participants with PD and healthy controls. Error
bars represent standard error of the mean. Facilitation was calculated
as mean response times in the congruent condition minus those in
the control condition. The congruent condition involved trials in which
the learned, spoken response to an image was the same as the
location where it was presented in Session 3. The control condition
consisted of new images in the experiment that were not associated
with any “right” or “left” responses. Control participants’
performance was equivalent across ON and OFF sessions and
therefore we used a combined control group. Participants with PD off
medication evidenced greater facilitation than participants with PD on
medication (F1,33 = 3.72, MSE = 9766.91, P = 0.062), and controls
(F1,47 = 3.74, MSE = 5719.86, P = 0.059) that trended toward
significance. (C) Mean interference scores for participants with PD
and healthy controls. Interference scores were calculated as mean
response times in the incongruent condition minus those in the
control condition. The incongruent condition involved trials in which
the learned, spoken response to an image was opposite to the
location where it was presented in Session 3. There were no
significant differences between participants with PD on or off
medication or relative to controls. Asterisks indicate level of
significance (**P < 0.05; *P < 0.1).

Session 2: Test phase
We performed a 2 9 2 ANOVA on “right” and “left”
spoken response accuracy during Session 2. Group (PD
vs. Control) and Medication Session (OFF vs. ON) were
between-subject factors. There were no significant main
effects (F < 1 for both Group and Medication Session) or
interactions, F1,61 = 1.97, MSE = 0.028, P = 0.165. Mean
error rates are presented in Table 2. A combined control
group was used in Table 2 to serve as a point of comparison between Sessions, given that there were no significant
differences between Sessions for controls.

Session 3: Facilitation and interference from
previous associations
Proportion of errors in the congruent, incongruent, and
control condition are presented in Table 2.
We performed a 2 9 2 ANOVA on facilitation scores
with Group (PD vs. Control) and Medication Session
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Table 2. Proportion of errors in Sessions 2 and 3.
Session 3

PD
OFF
ON
Combined control

Session 2

Congruent condition

Incongruent condition

Control condition

0.168 (0.036)
0.201 (0.041)
0.150 (0.043)

0.022 (0.012)
0.050 (0.009)
0.005 (0.003)

0.038 (0.029)
0.058 (0.012)
0.010 (0.006)

0.026 (0.015)
0.051 (0.008)
0.003 (0.003)

All values reported are group means (SEM). Proportion of errors in Session 2 was measured by the number of incorrect responses to the images
based on the associations learned in Session 1. In Session 3, trials where the participant answered with the incorrect response as to the location
of the image (i.e., left or right of center) are considered errors. In the congruent condition, an image appeared in a location that was consistent
with the spoken response that had been learned for that image during Session 1. In the incongruent condition, an image appeared in a location
that was opposite to the spoken response that had been learned for that image during Session 1. In the control condition, a new image that was
not previous associated with “right” or “left” was presented. Control participants’ performance was equivalent across sessions and therefore a
combined control group was used. PD = Parkinson’s disease.

(ON vs. OFF) as between-subject factors. Facilitation was
calculated as mean response times in the congruent condition minus those in the control condition. Again, the
congruent condition involved trials in which the learned,
spoken response to an image was the same as the location
where it was presented in Session 3. The control condition consisted of new images that the participant had not
previously associated with a “right” or “left” response.
The main effects of Group and Medication Session were
not significant, F < 1 and F1,61 = 2.60, MSE = 5700.11,
P = 0.112, respectively. The Group 9 Medication Session
interaction trended toward significance, F1,61 = 3.19,
MSE = 5700.11, P = 0.073, which was explored further in
one-way ANOVAs below.
One-way ANOVAs with Medication Status (ON vs.
OFF) as the between-subject factor were performed for
PD and Control participants’ data separately. These
revealed an ON-OFF difference for participants with PD
that
trended
toward
significance,
F1,33 = 3.72,
MSE = 9766.91, P = 0.062, but no ON-OFF difference for
controls, F < 1. Participants with PD showed greater
facilitation off relative to on medication (Fig. 4B).
Next, we compared facilitation for participants with
PD on versus off medication relative to controls. Control
participants’ performance was equivalent across sessions
and therefore we used a combined control group. Participants with PD off medication experienced significantly
more facilitation from previous associations than did participants with PD on medication or controls, F2,62 = 3.49,
MSE = 5610.07, P = 0.037. Comparing PD ON to the
combined control group revealed no significant differences in facilitation scores, F1,44 = 2.08, MSE = 2375.17,
P > 0.156, whereas the comparison of PD OFF to combined control group trended toward significance,
F1,47 = 3.74, MSE = 5719.86, P = 0.059, reflecting
enhanced facilitation for PD OFF compared to controls.
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We performed analogous analyses on interference
scores. Interference scores were calculated as mean
response times in the incongruent condition minus those
in the control condition. The incongruent condition was
composed of trials where the learned spoken response to
an image was opposite to the location of the image in
Session 3. The main effects of Group and Medication Session, both F1,61 < 1, and the Group 9 Medication Session
interaction, F1,61 < 1, were nonsignificant (Fig. 4C).

Discussion
We showed that stimulus-response association learning in
participants with PD, without a coexisting diagnosis of
dementia, is comparable to healthy controls off medication. This learning is impaired by dopaminergic medication. Regardless of medication status, recall of previously
learned stimulus-response associations and response selection performance for participants with PD were equal to
that of age-matched controls. Our four-group design
countered any carry-over effects that related to medication status during the learning phase. That is, we ensured
that the ON and OFF groups in Sessions 2 and 3 on Day
2 were composed of a similar number of participants with
PD who had acquired stimulus-response associations on
compared to off dopaminergic therapy in Session 1.
In Session 3, participants named the location of stimuli
– “right” or “left” of center – as quickly and accurately as
they could. Off medication, participants with PD evidenced
greater response facilitation than their counterparts who
were tested on medication or controls when the location
response in Session 3 was congruent with the response that
they had learned for particular stimuli in Session 1. Facilitation from congruent influences on responding has been
interpreted as evidence of impulsivity in children23 and
adolescents24 relative to adults, as well as in patients with
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attention deficit hyperactivity disorder,25 schizophrenia,26
and PD.27 Despite this, for all participants, no significant
interference occurred in Session 3 when stimuli occurred
in the location opposite to the spoken “right” or “left”
response paired with them in Session 1. Dissociations
between facilitation and interference effects in similar paradigms are commonly noted.11,28–30

Learning and decision performance in PD
We found that stimulus-response association learning is
spared in PD but is impaired by dopaminergic therapy.
A number of studies have also revealed normal probabilistic, associative, or motor sequence learning in participants with PD at baseline. In these studies, impairments
also arose due to dopaminergic medication.5,9–13,31 Others
have shown an opposite pattern, however.19,20 Recalling
and performing previously learned responses were not
affected by PD or dopaminergic medication, suggesting
that learning stimulus-response associations and recalling
and performing responses based on previous learning are
mediated by different brain regions. Cognitive functions
worsened by dopaminergic therapy have been widely
ascribed to brain regions that are innervated by the
VTA.2,32 The VTA is relatively spared compared to the
substania nigra SN in PD.2 Dopamine replacement is
titrated to the DS-mediated motor symptoms, effectively
overdosing VTA-innervated brain regions that are relatively dopamine replete.2,4 These include VS, limbic, and
prefrontal cortex. Indeed, using neuroimaging and behavioral methods, VS has been implicated in learning in
healthy participants and in participants with PD.11,31,32 In
a recent study, we in fact showed that VS activity correlated specifically with stimulus-response association learning at the time of feedback, whereas DS activation was
associated with response selection and enactment.33

Impulsivity in PD
Off medication, participants with PD seemed to experience enhanced facilitation for location responses that corresponded to the specific “right” or “left” response that
they had associated with an image in Session 1. We interpret this finding as evidence of more impulsive responding for participants with PD off medication. This was
relative to participants with PD who were tested on medication and healthy controls. At first glance, this finding
seems at odds with the popularly reported problems with
impulse control, such as pathological gambling, overeating, or excessive shopping, that arise as side effects of
dopaminergic medication, particularly dopamine agonists
in PD.34 Understanding that impulsivity is not a unitary
concept perhaps accounts for this discrepancy.
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One facet of impulsivity involves a predisposition to
decisions that favor short-term over long-term rewards or
consequences.35,36 This form of impulsivity is captured by
experimental paradigms such as the delayed discounting
task, which involves choosing between small immediate
rewards and larger delayed rewards.37 Participants with
PD on dopamine agonists tend to impulsively choose
immediate more often than delayed rewards.37 Impulsive
choices in these paradigms seem coherent with impulse
control disorders. Both are precipitated by dopaminergic
medication in PD, and are associated with activity
changes in medial frontal, posterior cingulate, as well as
VS (i.e., VTA-innervated brain regions).38
Impulsivity also manifests as a failure to inhibit motor
responses that are ongoing or prepotent, resulting in impetuous actions (i.e., motor impulsivity) or as premature
responding before sensory evidence is adequately sampled
(i.e., reflection impulsivity).36 Our experimental paradigm
indexes these forms of impulsivity and consistent with our
findings, previous studies have shown increased impulsivity
in participants with PD at baseline.39 Participants with PD
off medication select more prominent stimuli39 or more
practised responses40 faster than controls. Further, as we
have found here, this enhanced impulsivity is normalized
by dopaminergic therapy.39–41 This pattern of findings in
participants with PD is consistent with the fact that DS is
implicated in mitigating these forms of impulsivity.39–42 In
PD, DS is dopamine depleted at baseline, which is remedied
by dopaminergic medication.
Consistent with this view, we have previously argued
that DS is implicated in decision making, promoting
more distributed attention and integration of variable
influences on responding.29 DS mediates resisting attentional capture by more salient aspects of a situation or
reflexive enactment of more automatic responses to produce more deliberate and considered responses.29 When
DS is impaired, as in unmedicated PD, increased motor
or reflexive impulsivity is expected. When targets are salient or correct responses are overlearned and automatic,
PD patients’ performance is superior to healthy controls.
In contrast, poorer performance results when less salient
aspects of the context are more relevant to the current
goal or less practised responses are demanded.11,41

Summary
At baseline in PD, learning stimulus-response associations
is comparable to learning in healthy controls. In contrast,
stimulus-response learning is impaired by dopaminergic
therapy in PD. Recalling and selecting responses based on
previous learning was not affected by PD or dopaminergic
medication status. Off medication, however, there was a
trend in the data suggesting that participants with PD
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produced more impulsive responses than controls. This
tendency was redressed by dopaminergic therapy. This
pattern of results could suggest that learning stimulusresponse associations relies on VTA-innervated brain
regions. In contrast, the effect of PD and medication on
motor and reflexive impulsivity is consistent with the
view that these are DS mediated. These brain regions are
differentially dopamine depleted and hence dissimilarly
affected by dopaminergic therapy in PD.
Here, we add our results to a growing literature that
suggests that learning in various forms is impaired by
dopaminergic therapy. This effect of dopaminergic medication occurred only when stimulus-response associations were being learned and not when selections were
guided by previous learning. A further important insight
gained from this study is that some forms of impulsivity
occur at baseline in PD. These results highlight the fact
that impulsivity is not a unitary concept. Not all facets
of impulsivity arise in PD as a consequence of dopaminergic therapy. Indeed, here we present impulsive
responding that is normalized by dopaminergic therapy.
Our findings have implications for dopaminergic treatment in PD.
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